title: Are RNAi and miRNA therapeutics truly dead?
abstract: Only a few years ago pharmaceutical companies were excited about the potential of RNA interference (RNAi). Now, financial volatility and subsequent dissolutions of in-house facilities by pharmaceutical companies have had media channels pronouncing that RNAi therapeutics are dead. However, advances in nanomedicine may now help the vast potential of RNAi therapeutics to be fulfilled.
authors.affiliation: Massachusetts Institute of Technology (MIT), Institute for Medical Engineering and Science, Harvard-MIT Division for Health Sciences and Technology, Cambridge, MA, USA; School of Engineering and Materials Science, Queen Mary University of London, London, UK. Electronic address: jdconde@mit.edu.
authors.forename: João
authors.initials: J
authors.lastname: Conde
authors.affiliation: Massachusetts Institute of Technology (MIT), Institute for Medical Engineering and Science, Harvard-MIT Division for Health Sciences and Technology, Cambridge, MA, USA; Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: nartzi@mit.edu.
authors.forename: Natalie
authors.initials: N
authors.lastname: Artzi
mesh_terms: D020868:Gene Silencing; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D006801:Humans; D035683:MicroRNAs / Q000627:therapeutic use*; D050997:Nanomedicine / Q000379:methods / Q000639:trends
chemical_list: D035683:MicroRNAs
keywords: RNAi; biomaterials; delivery vehicle; nanotechnology; pharmaceutical companies